Dr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 Study of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

María-Victoria Mateos, MD, PhD, consultant physician, Hematology Department, associate professor of medicine, University of Salamanca, discusses long-term overall survival data from the phase 3 CARTITUDE-4 trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel; Carvykti) in lenalidomide (Revlimid)-refractory multiple myeloma.

News

® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Immuno-Oncology

EBMT Meeting

María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.